Previous 10 | Next 10 |
2023-11-22 23:31:20 ET Summary ARK Genomic Revolution ETF focuses on genomic innovation in sectors such as healthcare, information technology, and energy. The fund's buying and selling activity gives us clues about the degrees of conviction relative to its main holdings. The f...
2023-11-22 11:45:00 ET Cathie Wood has been surprisingly quiet on the trading front lately. The Ark Invest co-founder and CEO refrained from making any buys or sells for three consecutive trading days before finally making some moves on Tuesday. What did she do? The aggressive growth in...
2023-11-22 09:45:00 ET Analysts on Wall Street sometimes assign one-year price targets to stocks that imply massive upside potential. That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX) , an innovative biotech. The company's shares are currently changing hands for ...
2023-11-21 09:27:03 ET More on Nvidia, Roche, etc. Nvidia Q3 Earnings Preview: Know The Risks And The Reward Nvidia: Smooth Sailing Nvidia Fiscal Q3 Earnings Preview: Big Wave Surfing 4 stocks to watch on Tuesday: Nvidia, Abercrombie & Fitch and more ...
2023-11-21 08:00:00 ET Cathie Wood can't get enough of Recursion Pharmaceuticals (NASDAQ: RXRX) stock. Through her Ark Innovation ETF , the maverick growth stock portfolio manager bought shares of the biotech three times, expanding her position from a mere 61,000 shares to rough...
2023-11-16 12:35:07 ET Summary Recursion Pharmaceuticals, Inc. proof-of-concept data, from the phase 2 SYCAMORE study using REC-994 for the treatment of patients with Cerebral Cavernous Malformation, expected in the 2nd half of 2024. Safety and preliminary efficacy data, from the ...
2023-11-15 11:22:19 ET More on ARKG, ARKK, etc. ARKK ETF: There Are Better Options Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble ARKK: Outlook For Cathie Wood's ARK Innovation ETF Cathie Wood's ARK Invest l...
Recursion Pharmaceuticals Inc. (RXRX) is expected to report $-0.38 for Q3 2023
Berlin, Germany and Salt Lake City, USA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have updated the focus of their research collaboration to pre...
2023-11-09 08:14:06 ET More on Recursion Pharmaceuticals Recursion Pharmaceuticals: Wet Lab Meets Silicon, A Tale Of Two Bottom Lines Recursion Pharmaceuticals: Leveraging AI To Decode Biology And Discover Novel Therapeutics AI to represent 11% of healthcare budgets ...
News, Short Squeeze, Breakout and More Instantly...
Recursion Pharmaceuticals Inc. Company Name:
RXRX Stock Symbol:
NASDAQ Market:
Recursion Pharmaceuticals Inc. Website:
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,...